Global Cat Allergy Pipeline Review, H2 2016 - 3 Companies & 5 Molecules - Research and Markets

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Cat Allergy - Pipeline Review, H2 2016" report to their offering.

Cat Allergy pipeline therapeutics constitutes close to 5 molecules. Out of which approximately 5 molecules are developed by Companies. Our latest report Cat Allergy - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Cat Allergy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

Cat Allergy Cat allergy is an allergic reaction to one or more allergens produced by cats. Symptoms include sneezing, runny or stuffy nose, facial pain (from nasal congestion), coughing, chest tightness, shortness of breath and wheezing, watery, red or itchy eyes and skin rash or hives. The molecules developed by Companies in Phase II, Preclinical and Discovery stages are 1, 2 and 2 respectively.

Furthermore, this report also reviews of key players involved in therapeutic development for Cat Allergy and features dormant and discontinued projects.

Key Topics Covered:

1. Introduction
2. Cat Allergy Overview
3. Therapeutics Development
4. Pipeline Products for Cat Allergy - Overview
5. Pipeline Products for Cat Allergy - Comparative Analysis
6. Cat Allergy - Therapeutics under Development by Companies
7. Cat Allergy - Therapeutics under Investigation by Universities/Institutes
8. Cat Allergy Products Glance
9. Late Stage Products
10. Clinical Stage Products
11. Early Stage Products
12. Cat Allergy - Products under Development by Companies
13. Cat Allergy - Products under Investigation by Universities/Institutes
14. Cat Allergy - Companies Involved in Therapeutics Development

• ALK-Abello A/S
• Amgen Inc.
• Biomay AG

For more information about this report visit http://www.researchandmarkets.com/research/b43n5c/cat_allergy